CJC-1295 is a synthetic peptide that stimulates the release of growth hormone (GH) by acting on growth hormone–releasing hormone (GHRH) receptors. It increases GH and indirectly raises IGF-1 levels, supporting muscle recovery, fat loss, and improved sleep. There are two forms: CJC-1295 with DAC (drug affinity complex), which has a long half-life, and without DAC, which is shorter acting. It is usually administered by subcutaneous injection. CJC-1295 is mainly used in research and performance-enhancement communities. It is not approved for medical use by major regulatory agencies. Potential side effects include water retention, flushing, headache, and tingling sensations.
Dosing CJC-1295 (without DAC): protocol presents a practical once-daily subcutaneous approach using a dilution optimized for clear insulin-syringe measurements.
Reconstitute: Add 3.0 mL bacteriostatic water 1.67 mg/mL concentration.
Typical daily range: 100–300 mcg once daily (gradual titration).
Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 insulin syringe.